PROM1 and metastatic malignant neoplasm: Furthermore, higher CD133+ EV concentrations are associated with a lower overall response rate to first-line systemic therapy, and high concentrations might serve as biomarkers to improve risk stratification and to optimize treatment strategies in metastatic cancer [162].